CSPC Pharmaceutical CSPCY Stock
CSPC Pharmaceutical Price Chart
CSPC Pharmaceutical CSPCY Financial and Trading Overview
CSPC Pharmaceutical stock price | 2.77 USD |
Previous Close | 3.34 USD |
Open | 3.43 USD |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 3.38 - 3.43 USD |
52 Week Range | 3.25 - 5.35 USD |
Volume | 185.98K USD |
Avg. Volume | 108.5K USD |
Market Cap | 10.24B USD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 11.7589655 |
EPS (TTM) | 0.2 USD |
Forward Dividend & Yield | 0.11 (3.20%) |
Ex-Dividend Date | June 5, 2023 |
1y Target Est | N/A |
CSPCY Valuation Measures
Enterprise Value | 9.95B USD |
Trailing P/E | 11.7589655 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.3364345 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
CSPC Pharmaceutical Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -3.53% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.35 USD |
52 Week Low | 3.25 USD |
50-Day Moving Average | 3.78 USD |
200-Day Moving Average | 4.16 USD |
CSPCY Share Statistics
Avg. Volume (3 month) | 108.5K USD |
Avg. Daily Volume (10-Days) | 237.87K USD |
Shares Outstanding | 2.98B |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.029% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.3423 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | 10.38 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | N/A |
Diluted EPS (ttm) | 0.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | 10.136 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of CSPC Pharmaceutical
Country | United States |
State | N/A |
City | Shijiazhuang |
Address | No. 226 Huanghe Street |
ZIP | 050035 |
Phone | 86 31 1870 37015 |
Website | https://www.cspc.com.hk |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 24837 |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. The company was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Q&A For CSPC Pharmaceutical Stock
What is a current CSPCY stock price?
CSPC Pharmaceutical CSPCY stock price today per share is 2.77 USD.
How to purchase CSPC Pharmaceutical stock?
You can buy CSPCY shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CSPC Pharmaceutical?
The stock symbol or ticker of CSPC Pharmaceutical is CSPCY.
Which industry does the CSPC Pharmaceutical company belong to?
The CSPC Pharmaceutical industry is Drug Manufacturers-General.
How many shares does CSPC Pharmaceutical have in circulation?
The max supply of CSPC Pharmaceutical shares is 2.97B.
What is CSPC Pharmaceutical Price to Earnings Ratio (PE Ratio)?
CSPC Pharmaceutical PE Ratio is 13.84999900 now.
What was CSPC Pharmaceutical earnings per share over the trailing 12 months (TTM)?
CSPC Pharmaceutical EPS is 0.2 USD over the trailing 12 months.
Which sector does the CSPC Pharmaceutical company belong to?
The CSPC Pharmaceutical sector is Healthcare.